Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Drug Toxicity: Allergic Reactions01:30

Drug Toxicity: Allergic Reactions

Drug-related allergies are immune-mediated responses triggered by the administration of pharmacological agents. These hypersensitivity reactions are classified based on the immune mechanisms involved. The four primary types—Type I, II, III, and IV—are mediated by different immunological pathways and exhibit distinct clinical manifestations.Type I Hypersensitivity/ IgE-Mediated Reactions: Immunoglobulin E (IgE) immediately mediates Type I hypersensitivity reactions. Upon initial exposure to a...
Hypersensitivities01:30

Hypersensitivities

Hypersensitivity, also known as a hypersensitivity reaction or allergic reaction, is a condition where the body's immune system reacts abnormally to a foreign substance. Such substances, that cause hypersensitivity are referred to as an allergen, could be something typically harmless to most people, like pollen or certain foods.
Types of Hypersensitivities
Hypersensitivity reactions are categorized into four types: Type 1, Type 2, Type 3, and Type 4. Each type has a distinct mechanism...
Hypersensitivity Reactions: Immune-Complex Reactions01:19

Hypersensitivity Reactions: Immune-Complex Reactions

Type III hypersensitivity reactions occur when antigen–antibody complexes form and activate the complement system. Normally, these complexes help the clearance of antigens by phagocytes and red blood cells. However, when large numbers of immune complexes are present, they can deposit in tissues—particularly in the walls of blood vessels—leading to inflammation and tissue injury. These deposits trigger complement activation and neutrophil recruitment, resulting in serum sickness, a systemic...
Drug toxicity: Idiosyncratic Reactions01:16

Drug toxicity: Idiosyncratic Reactions

Idiosyncratic drug reactions represent abnormal chemical responses that vary significantly among individuals, ranging from extreme sensitivity to low doses to insensitivity to high doses. These reactions often occur due to the drug's covalent binding with serum proteins, forming a foreign hapten that triggers an immunotoxicological response. The variability in drug reactions has a strong pharmacogenetic foundation, with genetic differences crucial in how individuals metabolize drugs. For...
Hypersensitivity Reactions: Delayed Hypersensitivity Reactions01:29

Hypersensitivity Reactions: Delayed Hypersensitivity Reactions

Delayed-Type Hypersensitivity (DTH), or Type IV hypersensitivity, is a cell-mediated immune response. It occurs when T cells, rather than antibodies, mediate a reaction to specific antigens. It is characterized by a delayed onset (1-2 days) and involves the recruitment of macrophages to the inflammation site.The initiation of a DTH response begins with the sensitization of T cells. During this phase, which lasts at least 1-2 weeks, antigen-specific T cells are activated, clonally expanded, and...
Allergic Reactions: Anaphylaxis01:30

Allergic Reactions: Anaphylaxis

Anaphylaxis is a severe, life-threatening hypersensitivity reaction mediated by Immunoglobulin E (IgE) antibodies. When IgE binds to allergens, it triggers the release of mediators– histamine, leukotrienes, and prostaglandins from mast cells and basophils. These mediators cause vasodilation, edema, and inflammation, leading to various symptoms.The primary allergens causing anaphylaxis include food items (e.g., peanuts, shellfish), drugs (e.g., penicillin, asparaginase, corticotropin, heparin),...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Real-world 5-year outcomes with durvalumab after chemoradiotherapy in unresectable stage III NSCLC.

ESMO open·2026
Same author

Real-world outcomes with durvalumab after chemoradiotherapy in patients with unresectable stage III NSCLC: interim analysis of overall survival from PACIFIC-R.

ESMO open·2024
Same author

Cancer outpatients during the COVID-19 pandemic: what Oncoral has to teach us about medical drug use and the perception of telemedicine.

Journal of cancer research and clinical oncology·2023
Same author

Transarterial chemoembolization followed by moderately hypofractionated radiotherapy in hepatocellular carcinoma: Long-term results of RTF3 regimen.

Cancer radiotherapie : journal de la Societe francaise de radiotherapie oncologique·2023
Same author

[Management of immunotherapy in patients with non-small cell lung cancer presenting durable oncological response].

Revue des maladies respiratoires·2022
Same author

Final results of the IFCT-0803 study, a phase II study of cetuximab, pemetrexed, cisplatin, and concurrent radiotherapy in patients with locally advanced, unresectable, stage III, non-squamous, non-small-cell lung cancer.

Cancer radiotherapie : journal de la Societe francaise de radiotherapie oncologique·2022
Same journal

[Respiratory Medicine and Research: The new SPLF's anglophone journal].

Revue de pneumologie clinique·2018
Same journal

[Medical journals publication: Let's change].

Revue de pneumologie clinique·2018
Same journal

[Multiple ulcerated tracheobronchial mucosal lesions in the eosinophilic granulomatosis with polyangiitis].

Revue de pneumologie clinique·2018
Same journal

[Medium and long-term respiratory outcome in patients operated from congenital diaphragmatic hernia: From a series of 56 patients].

Revue de pneumologie clinique·2018
Same journal

[Sporadic lymphangioleiomyomatosis: A rare cause of bilateral spontaneous pneumothorax in young woman].

Revue de pneumologie clinique·2018
Same journal

[COPD and smoking cessation: Patients' expectations and responses of health professionals].

Revue de pneumologie clinique·2018
See all related articles

Related Experiment Video

Updated: Jul 3, 2026

A Salt-Templated Synthesis Method for Porous Platinum-based Macrobeams and Macrotubes
13:08

A Salt-Templated Synthesis Method for Porous Platinum-based Macrobeams and Macrotubes

Published on: May 18, 2020

[Platinum salts hypersensitivity].

S Couraud1, C Planus, C Rioufol

  • 1Service de radiothérapie et oncologie, Centre hospitalier Lyon Sud, 165 Chemin du Grand-Revoyet, Pierre-Bénite cedex, France.

Revue De Pneumologie Clinique
|July 8, 2008
PubMed
Summary
This summary is machine-generated.

Platinum salt hypersensitivity reactions often occur after 4-8 treatment courses, with longer platinum-free intervals increasing risk. Diagnosis involves skin tests like prick tests and intradermal reactivity (IDR), guiding management from desensitization to avoidance.

More Related Videos

Amide Coupling Reaction for the Synthesis of Bispyridine-based Ligands and Their Complexation to Platinum as Dinuclear Anticancer Agents
07:20

Amide Coupling Reaction for the Synthesis of Bispyridine-based Ligands and Their Complexation to Platinum as Dinuclear Anticancer Agents

Published on: May 28, 2014

Related Experiment Videos

Last Updated: Jul 3, 2026

A Salt-Templated Synthesis Method for Porous Platinum-based Macrobeams and Macrotubes
13:08

A Salt-Templated Synthesis Method for Porous Platinum-based Macrobeams and Macrotubes

Published on: May 18, 2020

Amide Coupling Reaction for the Synthesis of Bispyridine-based Ligands and Their Complexation to Platinum as Dinuclear Anticancer Agents
07:20

Amide Coupling Reaction for the Synthesis of Bispyridine-based Ligands and Their Complexation to Platinum as Dinuclear Anticancer Agents

Published on: May 28, 2014

Area of Science:

  • Oncology
  • Clinical Pharmacology
  • Allergy and Immunology

Background:

  • Platinum-based chemotherapy is a cornerstone in various cancer treatments.
  • Hypersensitivity reactions (HSRs) to platinum compounds are a significant clinical challenge, potentially limiting treatment efficacy.
  • Understanding the timing, risk factors, and diagnostic modalities for platinum HSRs is crucial for patient management.

Purpose of the Study:

  • To review the clinical manifestations, diagnostic approaches, and management strategies for platinum salt hypersensitivity reactions.
  • To highlight the role of skin testing, including prick tests and intradermal reactivity (IDR), in diagnosing platinum HSRs.
  • To provide guidance on re-introduction or replacement of platinum agents based on reaction severity and diagnostic results.

Main Methods:

  • Retrospective analysis of clinical data and diagnostic test results.
  • Evaluation of skin tests: prick tests and intradermal reactivity (IDR) with sequentially diluted platinum salts.
  • Assessment of reaction timing, clinical presentation, and patient outcomes following diagnostic tests and management interventions.

Main Results:

  • Platinum HSRs typically manifest after 4 to 8 treatment courses.
  • Longer platinum-free intervals are associated with an increased risk of HSRs.
  • Skin tests, particularly IDR performed 30 minutes prior to platinum salt administration, show promise as predictive diagnostic tools.

Conclusions:

  • Platinum salt hypersensitivity reactions require careful diagnosis using skin tests, especially in acute cases.
  • Management strategies vary from desensitization protocols for mild reactions to complete avoidance for severe reactions.
  • Intradermal reactivity testing can inform decisions regarding the re-introduction or substitution of platinum agents.